Ian Crozier
Christchurch Hospital
166 Papers
1K Citations
Ian Crozier is an academic researcher from Christchurch Hospital. The author has contributed to research in topics: Medicine & Ebola virus. The author has an hindex of 40, co-authored 142 publications. Previous affiliations of Ian Crozier include College of Health Sciences, Bahrain & World Health Organization.
Chat about Author
Papers
Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors
Jun Liu,John C. Trefry,April M. Babka,Christopher W. Schellhase,Kayla M. Coffin,Janice A Williams,Jo Lynne Raymond,Paul Facemire,Taylor B. Chance,N. Davis,Jennifer L. Scruggs,Franco Rossi,Andrew D. Haddow,Justine M. Zelko,Sandra L. Bixler,Ian Crozier,Patrick L. Iversen,Margaret L. Pitt,Jens H. Kuhn,Gustavo Palacios,Xiankun Zeng +20 more
TL;DR: It is discovered that EBOV, despite being cleared from all other organs, persisted in the brain ventricular system of rhesus macaque survivors that had received monoclonal antibody (mAb) treatment.
33
Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.
TL;DR: The addition of spironolactone produced a substantial diuresis associated with clinical and radiological improvement in each case, and this drug combination represents a therapeutic option in end-stage heart failure.
33
Being ready to treat Ebola virus disease patients.
David M. Brett-Major,Shevin T. Jacob,Frederique Jacquerioz,George F. Risi,William A. Fischer,Yasuyuki Kato,Catherine F Houlihan,Ian Crozier,Henry Kyobe Bosa,James V. Lawler,Takuya Adachi,Sara K. Hurley,Louise Berry,John C. Carlson,Thomas. C. Button,Susan McLellan,Barbara J. Shea,Gary G. Kuniyoshi,Mauricio Ferri,Srinivas Murthy,Nicola Petrosillo,Francois Lamontagne,David T. Porembka,John S. Schieffelin,Lewis Rubinson,Tim O'Dempsey,Suzanne M. Donovan,Daniel G. Bausch,Robert A. Fowler,Tom Fletcher +29 more
TL;DR: Clinicians deployed by the World Health Organization into a wide range of clinical settings in West Africa distill key, practical considerations for working safely and effectively with patients with EVD.
The extravascular implantable cardioverter-defibrillator: The pivotal study plan.
Ian Crozier,David O'Donnell,Lucas V.A. Boersma,Francis Murgatroyd,Jaimie Manlucu,Bradley P. Knight,Ulrika Birgersdotter-Green,Christophe Leclercq,Amy Thompson,Robert T. Sawchuk,Sarah Willey,Christopher Wiggenhorn,Paul A. Friedman +12 more
TL;DR: The safety endpoint is freedom from major complications, while the efficacy endpoint is defibrillation success, both endpoints will be assessed against prespecified criteria.
30
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
Gerald Wirnsberger,Vanessa Monteil,Brett P Eaton,Elena Postnikova,Michael O. Murphy,Benedict Braunsfeld,Ian Crozier,Franz Kricek,Janine Niederhoefer,Alice Schwarzboeck,Helene Breid,Anna Sanchez Jimenez,Agnes Bugajska-Schretter,Alexander Dohnal,Christine Ruf,Romana Gugenberger,Astrid Hagelkrueys,Nuria Montserrat,Nuria Montserrat,Mike Holbrook,Chris Oostenbrink,Robert H. Shoemaker,Ali Mirazimi,Josef M. Penninger,Josef M. Penninger +24 more
TL;DR: In this article, all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01).
27